Shingo Kano

Medical & Biological Laboratories Co., Ltd. engages in the research, development, manufacture and sale of biological products. It operates through the Reagents and Investment segments. The Reagent segment supplies, manufactures, and sells clinical reagents and research reagents, and its related equipment and instruments. The Investment segment deals with investments on bio-related enterprises and mediates technical partnership. The company was founded on August 23, 1969 and is headquartered in Nagoya, Japan.

Aphoenix, Inc. is a holding company that operates as a chemical genomics firm. It specializes in the affinity purification technology using special nano-scale beads and other supporting technologies, such as medicinal chemistry, mass spectroscopy, informatics and molecular, biology. The firm exploits drugs, which lack known mechanisms of action as probes for discovering druggable targets, and then develop such compounds against validated targets. The company was founded in 2002 and is headquartered in Tokyo, Japan .